fasenra
astrazeneca (israel) ltd - benralizumab - solution for injection - benralizumab 30 mg / 1 ml - benralizumab - fasenra is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
onglyza 5 mg
astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
onglyza 2.5 mg
astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
zoladex la
astrazeneca (israel) ltd - goserelin as acetate - implant for injection - goserelin as acetate 10.8 mg/unit - goserelin - goserelin - prostate cancer suitable for hormonal manipulation.
zomig 2.5 mg
astrazeneca (israel) ltd - zolmitriptan - film coated tablets - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.
budicort turbuhaler 200 mcgdose
astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 200 mcg/dose - budesonide - budesonide - bronchial asthma.
budicort turbuhaler 100 mcgdose
astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 100 mcg/dose - budesonide - budesonide - bronchial asthma.
astrazeneca water for injections 10ml ampoule
astrazeneca pty ltd - water for injections -
astrazeneca water for injections 5ml ampoule
astrazeneca pty ltd - water for injections -
astrazeneca sodium chloride 0.9% 10ml injection bpampoule
astrazeneca pty ltd - sodium chloride -